ERYTHROMYCIN
LOE ApproachingNDATOPICALSOLUTION
Approved
Jun 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
14
Data completeness
3/8 — Basic
ERYTHROMYCIN by Eli Lilly and Company is clinical pharmacology microbiology erythromycin inhibits protein synthesis without affecting nucleic acid synthesis. First approved in 1980.
Drug data last refreshed 9h ago · AI intelligence enriched 13h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis without affecting nucleic acid synthesis. It is a topical solution formulation indicated for infections caused by susceptible gram-positive and gram-negative organisms, including Streptococcus pyogenes, Staphylococcus aureus, Mycoplasma pneumoniae, and Chlamydia trachomatis. The drug has been in clinical use since 1980 and remains a standard-of-care option for certain dermatological and ophthalmological infections.
LOE Approaching
As a mature product approaching loss of exclusivity with moderate competitive pressure (30), the brand team is likely focused on cost containment and generic transition planning rather than aggressive expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Microbiology Erythromycin inhibits protein synthesis without affecting nucleic acid synthesis. Erythromycin is usually active against the following organisms in vitro and in clinical infections: Streptococcus pyogenes (group A β-hemolytic), Alpha-hemolytic streptococci…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (14)
A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants
Started May 2025
49 enrolled
Healthy Participants
A Study in Healthy People to Test Whether Erythromycin Influences the Amount of BI 1291583 in the Blood
Started Apr 2025
20 enrolled
Healthy
Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers
Started Mar 2024
24 enrolled
Chronic Obstructive Pulmonary Disease
Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes
Started Mar 2024
140 enrolled
Premature Rupture of Membrane
A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)
Started Feb 2022
16 enrolled
Amyotrophic Lateral SclerosisHealthy Volunteer
Worked on ERYTHROMYCIN at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.